InnoCare’s Pipeline Data at EHA 2024 Congress

At the European Hematology Association (EHA) 2024 Hybrid Congress, the data from InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented, showcasing significant advancements in various areas of hematology research and treatment.

  1. Subcutaneous ICP-B02 (CM355): A Novel Bispecific CD20/CD3 Antibody Showed Promising Efficacy and Favorable Safety Profile in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (Abstract No.: P2097)
  • The study evaluated the safety, efficacy, and pharmacokinetics/pharmacodynamics of ICP-B02 in relapsed/refractory B-cell non-hodgkin lymphoma (NHL). Results demonstrated favorable safety and promising efficacy, with an overall response rate (ORR) of 100.0% and a complete response rate (CRR) of 77.8%.
  1. Preliminary Safety and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with ICP-248: A Novel BCL2 Inhibitor (Abstract No.: P1851)
  • Preliminary results indicated a well-tolerated safety profile and promising efficacy of ICP-248 in relapsed or refractory B-cell malignancies, with an ORR of 100% at the 100 mg dose level.
  1. A Phase II Study to Evaluate the Safety and Efficacy of Tafasitamab Combined with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: (Abstract No.: P2091)
  • The study demonstrated that the tafasitamab plus lenalidomide regimen is well-tolerated in Chinese population with good efficacy, with an ORR of 73.1% and a complete response rate (CR) of 32.7%.
  1. Orelabrutinib-Lenalidomide-Rituximab in Patients with Untreated Mantle Cell Lymphoma (MCL): Updated Results of the Polaris Study (Abstract No.: P1141)
  • The regimen showed potent antitumor activity and manageable safety in patients with untreated MCL, with an ORR of 85.8%.
  1. Orient Study: Orelabrutinib Addition to R-Chop-Like Regimen Adapted to Response in Treatment-Naïve Non-GCB DLBCL (Abstract No.: P1167)
  • All patients who completed 6-cycle therapy attained complete remission at the end of cycle 6, suggesting potential benefits from the orelabrutinib plus R-Chop-like regimen.
  1. Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib): as First-Line Induction Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma (Abstract No.: P1193)
  • The regimen demonstrated notable efficacy in achieving higher response rates among patients with newly diagnosed PCNSL, with a tolerable safety profile.
  1. Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (INHL) Intolerant to Prior BTK Inhibitors (BTKI) (Abstract No.: P2074)
  • Promising efficacy and safety data of orelabrutinib were observed in prior BTKi-intolerant iNHL patients.
  1. Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG): for First-Line Treatment of Chronic Lymphocytic Leukemia (Abstract No.: P680)
  • The regimen demonstrated rapid and deep molecular remission with a manageable safety profile in previously untreated CLL patients.
  1. Real-World Study: R-CHOP-like Regimen Plus Orelabrutinib in Different Subtypes of DLBCL Patients (Abstract No.: PB3034)
  • The study showed that patients with different subtypes of DLBCL benefit from the regimen, with a higher proportion of complete remissions observed when orelabrutinib was added earlier.

About InnoCare:
InnoCare (HKEX: 09969; SSE: 688428) is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. With branches in multiple locations, including Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States, InnoCare aims to address unmet medical needs in China and worldwide.

Source link

Newsletter Updates

Enter your email address below and subscribe to our newsletter